The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84) - Test2 - elhamkhani - TriplyDB

The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)

The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)

http://www.wikidata.org/entity/Q33984825

about

Bone disease in pediatric chronic kidney disease Fibroblast Growth Factor 23: A New Dimension to Diseases of Calcium-Phosphorus Metabolism Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease Lack of FGF23 response to acute changes in serum calcium and PTH in humans.Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients.Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.Early skeletal and biochemical alterations in pediatric chronic kidney disease.(1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.FGF-23 levels in patients with AKI and risk of adverse outcomes.Update on fibroblast growth factor 23 in chronic kidney disease.Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.Plasma FGF23 levels increase rapidly after acute kidney injury.FGF-23: the rise of a novel cardiovascular risk marker in CKD.The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.Circulating markers of bone turnover.Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels.

P2860

Q26864102-77964566-9FEA-4EA1-9A03-BBFE9CF6F0BA Q26866263-64AEC5C2-D0ED-4C5D-9E43-2C36B3F6841C Q27024043-E4277B5B-F09C-4E8F-B41C-E00CA7246FBE Q33570120-0D5CCDE3-2176-4F54-A573-6BEB1222333D Q33873467-3290E6C4-EC3E-4884-8D81-72595839C423 Q34366087-C2B50655-113E-49BD-852E-70940F793FB1 Q35664606-946451CF-062A-4A3E-9F0E-4FA03620D9C6 Q35682152-F99DF39D-5E94-49A6-BA65-7C31D1A4F6E0 Q35692418-541499D9-6E38-4C28-9431-D3AF28447E5C Q35692471-CB3131F1-7A6C-4503-B197-4936BC2206CF Q36126891-1F6EA7CF-FD79-4CCC-A0D2-EE4647900356 Q36210285-2B82FEA1-763B-470E-8CBE-893483947240 Q36368980-D1C5AAA6-8DFD-4EC4-970D-D76D9CEC4ACD Q36381365-378D9A2F-20C0-4959-8FB6-9296DD39F5F2 Q37154351-D30B6F18-C6E9-45BC-80A4-2C2A182C8DFF Q38031216-C86BD37A-9DF1-495D-BCD1-18AD7198971C Q38053246-7C15E70C-7B1B-4825-A168-C1330831D7F8 Q39304775-DD64F5AA-2E1A-4574-B802-771E42B39B89 Q42727533-DEBAED58-8499-4639-B946-0340B06C387C Q50785234-D2DBFED0-12A9-41A7-A271-4C9511A1727E

P2860

The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)

http://www.wikidata.org/entity/Q33984825

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The calcemic response to conti ...... a potential role for PTH(7-84)

@ast

The calcemic response to conti ...... a potential role for PTH(7-84)

@en

type

label

The calcemic response to conti ...... a potential role for PTH(7-84)

@ast

The calcemic response to conti ...... a potential role for PTH(7-84)

@en

prefLabel

The calcemic response to conti ...... a potential role for PTH(7-84)

@ast

The calcemic response to conti ...... a potential role for PTH(7-84)

@en

P1433

Q33984825-01478EB0-1360-4F7F-B9EC-3D371712B393

P1476

Q33984825-419119B3-E22C-4CF0-A2C6-3F4A07B98D1F

P2093

Q33984825-04F1D0EC-AB3B-4A48-AB35-8E81F6F66910

Q33984825-207215B8-E50B-4AF6-BDDC-D97460CB2ACE

Q33984825-34F47CA3-05AC-4C6D-9A04-BF8E4A57EBE3

Q33984825-545113A0-A87A-45EA-B948-4AEC88F686F1

Q33984825-78D1C35D-C708-4618-A228-FE407C1D4F4C

Q33984825-9FABCA3C-B720-4C41-BD65-1C5DD2715A42

Q33984825-C60C192B-688D-440A-8549-426E401CA197

Q33984825-EF5471F1-87FE-4DF3-9231-B89299A3EA99

P2860

Q33984825-0219C62D-0521-4200-914B-634AB5231A59

Q33984825-026BFB10-3E3E-43C6-BD50-28FBDBBE2850

Q33984825-0AA757BD-23F5-438B-BB9F-68F8742FB519

Q33984825-154B7476-757B-45B5-89A7-6EE0026B434E

Q33984825-1CC0D695-6F95-4F29-A0CE-7100BD9A8FA1

Q33984825-1DE94246-110B-4E2A-A277-93B244105695

Q33984825-281D84DE-DAD0-4AA4-8678-D98A9853BA49

Q33984825-2E0AF07C-91A9-46EA-9F00-CDA82D286D46

Q33984825-32DA9DE4-C967-48CB-A541-5C5D6899AECC

Q33984825-41F783AF-FF12-419E-BEE0-A666A65F0E74

P304

Q33984825-73ACCAD3-7B80-451A-8EE1-832E69C99593

P31

Q33984825-1816F9F2-6361-479D-8352-F2F8EED38867

P356

Q33984825-3F9791BD-D11C-4D4E-8D8B-1C74E47AAACB

P407

Q33984825-918AEF2C-D3CA-469F-8F99-78063E1040B1

P433

Q33984825-8BE49443-51D9-45E1-BE12-DCB7A8BC5F87

P478

Q33984825-7542C686-72F6-49F8-837B-54B576EBFABC

P50

Q33984825-3f4cde0e-425e-194a-b5d1-9357f7c0954a

P577

Q33984825-C9821F8B-25EB-44E9-A481-6AA65F08194C

P698

Q33984825-0BEF7F6A-D513-4435-A2AC-FEC0DFCBD001

P932

Q33984825-A2048296-3D72-44BF-8BB2-B0598A2C3559

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

The calcemic response to conti ...... a potential role for PTH(7-84)

@en

P2093

Andrew F Stewart

http://www.w3.org/2001/XMLSchema#string

Barbara Gales

http://www.w3.org/2001/XMLSchema#string

G Chris Harkins

http://www.w3.org/2001/XMLSchema#string

Harald Jüppner

http://www.w3.org/2001/XMLSchema#string

He-jing Wang

http://www.w3.org/2001/XMLSchema#string

Isidro B Salusky

http://www.w3.org/2001/XMLSchema#string

Katherine Wesseling-Perry

http://www.w3.org/2001/XMLSchema#string

Mara J Horwitz

http://www.w3.org/2001/XMLSchema#string

P2860

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice

The parathyroid is a target organ for FGF23 in rats

Magnesium stimulates renal phosphate reabsorption

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

Bone disease in children and adolescents undergoing successful renal transplantation.

Calcific uremic arteriolopathy in association with low turnover uremic bone disease.

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

P304

2772-2780

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2009-1909

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

Robert Elashoff

P577

2010-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20382692

http://www.w3.org/2001/XMLSchema#string

P932

2902063

http://www.w3.org/2001/XMLSchema#string